Advancing Multiple Sclerosis Treatment: Exploring Evolving Therapies and Patient-Centered Approaches

This activity was originally presented as a part of Neurology Pharmacy Day of Education 2025.

Program Description

Multiple sclerosis (MS) is a common immune-mediated demyelinating disease. While there have been advancements in understanding MS pathogenesis and developing disease-modifying therapies, many patients fail to respond due to lack of efficacy, adverse effects, poor tolerability, or poor adherence. Recently approved therapeutic agents, such as novel oral agents and monoclonal antibodies, are being developed to address these unmet medical needs for patients with relapsing and remitting MS. As frontline medication experts, pharmacists play a critical role in treatment selection, patient counseling, monitoring for adverse effects, and managing complex medication regimens. This session will review clinical guidelines, treatment goals such as preventing irreversible disability and reducing central nervous system inflammation, and best practices to provide informed, proactive support across the MS care continuum

Target audience: Specialty pharmacist

Type of activity: Application
Release date: June 20, 2025
Expiration date: June 20, 2026

Time to complete activity: 1.5 hours

Learner level: Intermediate, Advanced
Fee: Free

Educational Objectives

At the completion of this activity, participants will be able to:

• Examine the clinical challenges and unmet needs in managing relapsing and progressive forms of multiple sclerosis (MS)
• Compare the efficacy and safety profiles of current and investigational therapies for the management of MS
• Apply patient-centered approaches to care, focusing on education and support to enhance quality of life and treatment outcomes for individuals with MS

Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.5 contact hours (0.15 CEU) under the ACPE universal activity number 0290-0000-25-203-H01-P. The activity is available for CE credit through June 20, 2026.

Instructions for Completing the Activity and Receiving CPE Credit

To receive CPE credit, participants must complete the pretest, review the activity in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.

Disclosures

The following contributors have no relevant financial relationships with commercial interests to disclose:

Faculty

Aimee M. Banks, PharmD, BCPS, MSCS; Erica Marini, PharmD, MS, BCPS; and Jenelle Hall Montgomery, PharmD, BCACP, CPP

Pharmacy Times Continuing Education^™ Planning Staff—Jim Palatine, RPh, MBA; Maryjo Dixon, RPh, MBA; Liza Patel, PharmD; Kylie Ferrentino; Susan Pordon; Brianna Winters; and Chloe Taccetta

At least one anonymous peer reviewer was used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.

Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.

For questions about this internet CPE activity, please contact:
[email protected]
Privacy Policy and Terms of Use Information:
www.pharmacytimes.org/terms